About

 

"This is impressive to see how rapidly this young start-up with a small dedicated team has been able to set up a major collaboration with a big Pharma, and then to develop so quickly - and not hasttely - into a sizable Biotech with a very professional team."

Philippe Guinot, Chairman of the Board

Board of Directors

David Hallal

Chairman of the Board

David Hallal was appointed Chairman of iTeos Therapeutics in June 2018. He also currently serves as the Chairman of Scholar Rock (Nasdaq: SRRK) and is an independent director of Seer Biosciences.

David has 30 years of experience in the biopharmaceutical industry including over 10 years at Alexion Pharmaceuticals playing a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As CEO of Alexion, David transitioned the company from a single-product to a multi-product enterprise. This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate from a preclinical stage to registration trials in multiple diseases in just 18 months.

Prior to his appointment as CEO, David served as Alexion’s Chief Operating Officer and then Chief Commercial Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David also held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. David holds a BA in Psychology from the University of New Hampshire.

Back to top

Detlev Biniszkiewicz

Dr. Detlev Biniszkiewicz is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role at MPM. Currently, he is President and CEO of two early-stage biotech companies, Rekindle Therapeutics and NextPoint Therapeutics. 

Prior to joining MPM, Detlev was the President and CEO of Surface Oncology (NASDAQ: SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso®, two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical and academic collaborations, and external research. Detlev has also held multiple roles at Novartis including Global Head of Portfolio, where his group provided oversight of Novartis’ research and early development portfolio.

Detlev began his career at the Boston Consulting Group and performed his academic research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.

Back to top

Priyanka Belawat

Priyanka Belawat, Ph.D. is an Investment Advisor at HBM Partners AG. Priyanka has 11 years of experience in venture and private equity investing in the healthcare space. She has been instrumental in many portfolio investments of HBM funds in areas of biotech and pharma. Presently, she represents HBM funds on the board of Neurelis Inc. (USA, Epilepsy). Some of her previous investments include Advanced Accelerator Applications (NASDAQ:AAAP, exit to Novartis), ARMO Biosciences (NASDAQ:ARMO, exit to Eli Lilly) and TrueNorth Therapeutics (USA, exit to BioVerative). Priyanka holds a doctorate in Molecular Biology and Genetics from the University of Zurich and completed post-doctorate work at HKUST.

Back to top

Chris Buyse

Chris Buyse’s experience in international company finance and establishing best financial practices spans more than 20 years. Previously, as CFO of the Belgian biotechnology company CropDesign, he coordinated its acquisition by BASF in early 2007. Chris has also been Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and CFO and interim CEO of Keyware Technologies. He has also held financial positions at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever. Chris earned a Master’s degree in Economics from the University of Antwerp and an MBA from the Vlerick School in Ghent.

Back to top

Michel Detheux

Chief Executive Officer

Michel is a co-founder of iTeos and has served as Chief Executive Officer since the Company’s incorporation in 2011. Prior to iTeos, Michel gained 15 years of biotech expertise in target discovery, business development, managerial and commercial responsibilities at Euroscreen before joining Ludwig Cancer Research and founding iTeos.

Michel holds a Bioengineering degree and a Ph.D. in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School.

He has authored 51 peer-reviewed publications and is an inventor of 27 patents.

Back to top

Ansbert Gadicke

Ansbert Gadicke, M.D. co-founded MPM in 1997 with his partner Luke Evnin and was the lead investor and has served on the boards of several of MPM’s most successful investments including BioMarin, Idenix, Mitobridge, Pharmasset, and Radius. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and previously, he was at The Boston Consulting Group.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. He is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at MIT and the Biochemistry Department at Harvard University. While at the German Cancer Research Center he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.

Ansbert currently serves as Chairman of the Board at Cullinon Oncology and TCR2 Therapeutics and as a Board Director at ElevateBio.

Back to top

Jonathan Skipper

Jonathan Skipper, Ph.D. is Executive Vice President for Technology Development at the Ludwig Institute for Cancer Research, a program that provides pre-clinical, clinical and business development support for the development of Ludwig’s research discoveries. Jonathan has over 15 years’ experience in the management of intellectual property and technology licensing and has completed numerous partnering transactions with biopharma companies, including several Ludwig biotechnology start-ups. Jonathan received his Ph.D. in Immunology from University College London and completed further research at the University of Virginia and the University of Oxford.

Back to top

Tim Van Hauwermeiren

Tim Van Hauwermeiren, M.Sc. EMBA, has been the Chief Executive Officer and an Executive Director at argenx SE since July 2008 and July 2014 respectively. Tim co-founded argenx in 2008. He previously served as the Senior Business Development Manager of Ablynx NV where he developed broad business development and operational management experience. Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Prior to joining Ablynx, he held various management positions with Procter & Gamble in R&D and Corporate New Business Development. Tim holds B.Sc. and Master of Science degree in Bio-Engineering from the University of Ghent and received general management training at INSEAD. He also holds Executive MBA from the Vlerick School of Management.

Back to top

Wei Zhao

Board Observer

Wei Zhao, Ph.D. is a Vice President at 6 Dimensions Capital. Prior to that, Wei was a Senior Life Sciences Specialist at L.E.K. Consulting, and a postdoctoral fellow at Mass. Eye & Ear / Harvard Medical School. Wei holds a doctoral degree in Neuroscience from Northwestern University, and a Bachelor's degree in Biological Sciences from Tsinghua University.

Back to top